Table 5.

Recommended endoscopic surveillance intervals based on degree of dysplasia and segment length

Baseline endoscopic finding	Suggested endoscopic surveillance
Nondysplastic BE of <3 cm length	EGD every 5 yr
Nondysplastic BE of ≥3 cm length	EGD every 3 yr
BE indefinite for dysplasia, any length (confirmed by a second pathologist)	Repeat EGD within 6 mo after increasing PPI to twice-daily dosing, if not already on high-dose PPI If repeat EGD yields diagnosis of NDBE or LGD, treat using that algorithm If repeat EGD demonstrates BE indefinite for dysplasia, EGD annually
BE with LGD (confirmed by a second pathologist and opting for endoscopic surveillance)	EGD at 6 mo from diagnosis EGD 12 mo from diagnosis EGD annually thereafter

BE, Barrett’s esophagus; EGD, esophagogastroduodenoscopy; LGD, low-grade dysplasia; NDBE, nondysplastic BE; PPI, proton pump inhibitor.